Mode
Text Size
Log in / Sign up
N/A N=396

Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)

In Vitro Fertilization

Enrolled (actual)
396
Serious AEs
1.0%
Results posted
May 2015
Primary outcome: Primary: Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) — 32.1; 41.4 Percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
corifollitropin alfa (Drug); recFSH (follitropin alfa) (Biological); gonadatropin releasing hormone (GnRH) antagonist ganirelix (Drug); human chorion gonadatropin (hCG) (Drug); progesterone (Biological); placebo-recFSH (follitropin alfa) (Drug); placebo-corifollitropin alfa (Drug); open-label recFSH (Biological)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Organon and Co
Primary completion
Dec 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate)
32.1; 41.4
SECONDARY
Percentage of Participants in Follow up Study With a Miscarriage Per Clinical Pregnancy
13.6; 10.0
SECONDARY
Percentage of Participants in Follow up Study With a Miscarriage Per Vital Pregnancy
0.0; 0.0
SECONDARY
Percentage of Participants in Follow up Study With an Ecotopic Pregnancy
1.3; 0.0
SECONDARY
Percentage of Participants in Follow up Study With a Clinical Pregnancy
28.6; 40.0
SECONDARY
Percentage of Participants in Follow up Study With a Vital Pregnancy
24.7; 36.0
SECONDARY
Percentage of Participants With an Ongoing Pregnancy
23.4; 36.0

Summary

Clinical trial objective is to collect the outcome of Frozen-Thawed Embryo Transfer (FTET) cycles performed after the embryos are cryopreserved in the base study P05690 in order to estimate the cumulative pregnancy rate for each treatment group.

Eligibility Criteria

Inclusion Criteria

  • Participants from whom embryos have been cryopreserved in base study P05690, of which at least one embryo is thawed for use in a subsequent FTET cycle;
  • Able and willing to give written informed consent.

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00702546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search